These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 19014494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A.
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 6. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

  • 7. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.
    Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
    [Abstract] [Full Text] [Related]

  • 8. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
    Meza LA, Green MD, Hackett JR, Neumann TA, Holmes FA.
    Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389
    [Abstract] [Full Text] [Related]

  • 9. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, Avisar N.
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P.
    BMC Cancer; 2013 Aug 14; 13():386. PubMed ID: 23945072
    [Abstract] [Full Text] [Related]

  • 11. Development of a new G-CSF product based on biosimilarity assessment.
    Gascon P, Fuhr U, Sörgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M.
    Ann Oncol; 2010 Jul 14; 21(7):1419-1429. PubMed ID: 20019087
    [Abstract] [Full Text] [Related]

  • 12. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 13. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.
    Invest New Drugs; 2013 Oct 01; 31(5):1300-6. PubMed ID: 23677653
    [Abstract] [Full Text] [Related]

  • 14. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ, Lee-Ma A, Troxell LS, Chan J.
    Am J Health Syst Pharm; 2008 Aug 15; 65(16):1552-5. PubMed ID: 18693211
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K.
    BioDrugs; 2009 Aug 15; 23(1):43-51. PubMed ID: 19344191
    [Abstract] [Full Text] [Related]

  • 16. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM, Bias P, Buchner A.
    Support Care Cancer; 2016 Jan 15; 24(1):267-273. PubMed ID: 26024743
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N.
    Ann Oncol; 2018 Jan 01; 29(1):244-249. PubMed ID: 29091995
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I.
    BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980
    [Abstract] [Full Text] [Related]

  • 19. An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.
    Sveikata A, Liutkauskienė S, Juozaitytė E, Characiejus D, Tamošaitytė L, Šeštakauskas K.
    Medicina (Kaunas); 2011 Feb 06; 47(8):428-33. PubMed ID: 22123557
    [Abstract] [Full Text] [Related]

  • 20. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW, Moon YW, Mezei K, Láng I, Bhat G, Chawla S, Hasal SJ, Schwartzberg LS.
    Cancer Med; 2020 Sep 06; 9(17):6234-6243. PubMed ID: 32687266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.